Why is Fredun Pharma falling/rising?

As of 25-Aug, Fredun Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 1,266.80, reflecting an increase of Rs 12.75 or 1.02%. The stock has recently hit a new 52-week high of Rs 1,329 and has been on a positive trajectory, gaining 20.65% over the last three days. It opened with a gain of 2.47% today and has outperformed its sector by 0.61%. In terms of performance, the stock has shown impressive returns, with a 1-week increase of 19.99%, a 1-month increase of 39.21%, and a year-to-date rise of 71.83%. The company's strong fundamentals are underscored by consistent growth in net sales and operating profit, with net sales growing at an annual rate of 38.16% and operating profit at 56.18%. Additionally, the stock's attractive valuation, trading at a discount compared to peers, and a favorable PEG ratio of 0.7 further support its upward movement.
In the broader market context, Fredun Pharmaceuticals has significantly outperformed the benchmark index, with the BSE500 generating negative returns of -2.11% over the past year, while Fredun has achieved a remarkable 59.03% return. This stark contrast highlights the stock's resilience and appeal to investors, especially given the rising investor participation reflected in a 187.31% increase in delivery volume. However, it is worth noting that domestic mutual funds hold no stake in the company, which may indicate a lack of confidence at current price levels. Despite this risk, the stock's strong performance and positive financial results have contributed to its rising price.